You searched for "glaucoma"
Risk factors for NTG in a young Korean population
Previously known ocular and systemic risk factors for normal tension glaucoma (NTG) include myopia, peripapillary atrophy, disc haemorrhage, migraine, obstructive sleep apnoea, thyroid disease and cerebral infarction. However, most NTG risk factor studies have examined patients aged 40 years and...
Risk factors and untreated POAG
The authors examined 50 untreated open angle glaucoma patients to determine if there was an association between the level of glaucomatous damage and documented risk factors. In this study the authors measured the extent of morphologic and functional glaucomatous damage...
Macular thickness and visual fields
The authors describe a comparison of spectral domain OCT with Humphrey visual fields (HVF) mean deviation (MD) and pattern standard deviation (PSD), examining the retinal thickness of the macula and circumpapillary retinal nerve fibre layer (RNFL) defects. Seventy-three subjects who...
Arterial stiffness and PEX
The authors describe a study of 25 newly diagnosed patients with pseudoexfoliation glaucoma (PEX) and 25 controls to evaluate carotid femoral pulse wave velocity (CF-PWV) values. The CF-PWV was assessed using a noninvasive device by measuring the pulse transmit time...Dr Paul Singh and Prof Gus Gazzard on laser as first line therapy
Both the American Academy of Ophthalmology (AAO) and the European Glaucoma Society (EGS) have updated their preferred practice regimens to recognize or recommend SLT as an initial intervention for glaucoma and the NICE UK are now guiding doctors to use SLT before drops.Ultrasound biomicroscopy (part 2): primary angle closure
Patients with primary angle closure or primary angle closure glaucoma [PAC(G)] comprise a significant subgroup affecting around 10% of glaucoma patients amongst Caucasians. Assessment of the patient with angle closure, or narrow angles, requires gonioscopy. However, whilst identifying the presence...Rachel Price joins Glaukos as Territory Manager, South Wales
Glaukos Corporation is delighted to announce the appointment of Rachel Price to the position of Territory Manager, South Wales.
Hyphema after trabeculectomy with MMC
The authors retrospectively reviewed the medical records of consecutive patients with glaucoma who underwent trabeculectomy with mitomycin C between June 2005 and December 2010 to determine the risk factors for hyphema after surgery. Of the 420 patients, 104 (24.8%) had...Glaukos announce the launch of iStent Inject® W
Glaukos is delighted to announce availability in the UK of iStent inject® W – a development of the trabecular micro-bypass system.
Mono vs. multi-therapy in IOP control
This randomised control trial studied newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differences in initial intraocular pressure (IOP) reduction, target IOP levels reached and influence of untreated baseline IOP on IOP reduction. Patients newly diagnosed with manifest primary...Glaukos at the Royal College of Ophthalmologists Annual Congress 2019 – Stand 17b
Glaukos, the ophthalmic medical technology company dedicated solely to the transformation of the treatment of glaucoma, is delighted to be attending the Annual Congress in Glasgow in May 2019. Glaukos has a portfolio of cutting edge products including the revolutionary...
